Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can we spot cancer before it starts? a massive study aims to find out

NCT ID NCT05463796

NEW Recruiting now Knowledge-focused Sponsor: Dana-Farber Cancer Institute Source: ClinicalTrials.gov ↗

First seen Aug 17, 2026 · Last updated Aug 17, 2026

Summary

This study is building a large collection of blood, saliva, urine, stool, and tissue samples from people who are at increased risk of cancer, including those with genetic predispositions, survivors of childhood or adult cancer, or those with precancerous conditions. The goal is to identify early changes and risk factors that could predict cancer development. By tracking participants over time, researchers hope to find new markers for early detection and ways to intercept cancer before it becomes life-threatening.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Collection of biological samples (blood, saliva, urine, stool, tissue) for research
What this could lead to
If successful, this could lead to better ways to predict who will develop cancer and new strategies to stop it before it becomes serious.
What could go wrong
This is an observational study, so it won't directly test a treatment. It may take years to find useful markers, and the findings might not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADENOMATOUS HYPERPLASIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Barrett esophagus Carcinoma, Lobular cirrhosis of liver Endometrial Hyperplasia Fibrosis giant cell tumor hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm in situ carcinoma lung cancer lung neoplasm metabolic dysfunction-associated steatohepatitis metabolic dysfunction-associated steatotic liver disease mixed epithelioid and spindle cell melanoma Osteochondroma spitz nevus vulvar intraepithelial neoplasia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADENOMATOUS HYPERPLASIA ADULT CANCER SURVIVORS BARRETT ESOPHAGUS BENIGN BONE LESIONS WITH RISK OF MALIGNANT DEGENERATION CANCER PREDISPOSITION SYNDROME CANCER RISK CERVICAL AND ENDOCERVICAL CARCINOMA IN SITU CHILDHOOD CANCER SURVIVORS CIRRHOSIS COLONIC DYSPLASIA/ADENOMATA DUCTAL/LOBULAR CARCINOMA ENDOMETRIAL INTRAEPITHELIAL NEOPLASIA GIANT CELL TUMOR HEMATOLOGIC MALIGNANCY HEREDITARY CANCER PREDICTION HIGH GRADE PROSTATIC EPITHELIAL NEOPLASIA HIGH-GRADE BLADDER UROTHELIAL DYSPLASIA/CARCINOMA IN SITU HIGH-RISK ORAL PRECANCEROUS DISEASES IARC CARCINOGENS LUNG CANCER LUNG; NODE MELANOCYTIC LESION, ADULT NEPHROGENIC RESTS NON ALCOHOLIC STEATOHEPATITIS NON-ALCOHOLIC FATTY LIVER DISEASE OSTEOCHONDROMA PANCREATIC PRECURSOR LESIONS SEROUS TUBAL INTRAEPITHELIAL CARCINOMA SMOKING HISTORY SPITZ NEVUS VULVAR INTRAEPITHELIAL NEOPLASIA

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Dana Farber Cancer Institute

    RECRUITING

    Boston, Massachusetts, 02115, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.